Patient-reported outcome measures for use in clinical trials of SLE: a review

被引:33
作者
Izadi, Zara [1 ]
Gandrup, Julie [2 ]
Katz, Patricia P. [2 ]
Yazdany, Jinoos [2 ]
机构
[1] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Div Rheumatol, San Francisco, CA USA
来源
LUPUS SCIENCE & MEDICINE | 2018年 / 5卷 / 01期
关键词
QUALITY-OF-LIFE; SYSTEMIC-LUPUS-ERYTHEMATOSUS; CROSS-CULTURAL VALIDATION; B-LYMPHOCYTE STIMULATOR; FORM HEALTH SURVEY; IMPACT TRACKER; DISEASE-ACTIVITY; DOUBLE-BLIND; PSYCHOMETRIC PROPERTIES; RHEUMATOID-ARTHRITIS;
D O I
10.1136/lupus-2018-000279
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Inclusion of patient-reported outcomes is important in SLE clinical trials as they allow capture of the benefits of a proposed intervention in areas deemed pertinent by patients. We aimed to compare the measurement properties of health-related quality of life (HRQoL) measures used in adults with SLE and to evaluate their responsiveness to interventions in randomised controlled trials (RCTs). A systematic review was undertaken using full original papers in English identified from three databases: MEDLINE, EMBASE and PubMed. Studies describing the validation of HRQoL measures in English-speaking adult patients with SLE and SLE drug RCTs that used an HRQoL measure were retrieved. Twenty-five validation papers and 26 RCTs were included in the indepth review evaluating the measurement properties of 4 generic (Medical Outcomes Study Short-Form 36 (SF36), Patient Reported Outcomes Measurement Information System (PROMIS) item-bank, EuroQol-5D, and Functional Assessment of Chronic Illness Therapy-Fatigue) and 3 disease-specific (Lupus Quality of Life (LupusQoL), Lupus Patient Reported Outcomes, Lupus Impact Tracker (LIT)) instruments. All measures had good convergent and discriminant validity. PROMIS provided the strongest evidence for known-group validity and reliability among generic instruments; however, data on its responsiveness have not been published. Across measures, standardised response means were generally indicative of poor-moderate sensitivity to longitudinal change. In RCTs, clinically important improvements were reported in SF36 scores from baseline; however, between-arm differences were frequently non-significant and non-important. SF36, PROMIS, LupusQoL and LIT had the strongest evidence for acceptable measurement properties, but few measures aside from the SF36 have been incorporated into clinical trials. This review highlights the importance of incorporating a broader range of SLE-specific HRQoL measures in RCTs and warrants further research that focuses on longitudinal responsiveness of newer instruments.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Patient-Reported Outcomes for Quality of Life in SLE: Essential in Clinical Trials and Ready for Routine Care
    Nguyen, Matthew H.
    Huang, Frank F.
    O'Neill, Sean G.
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (16)
  • [2] International guidance on the selection of patient-reported outcome measures in clinical trials: a review
    Norah L. Crossnohere
    Michael Brundage
    Melanie J. Calvert
    Madeleine King
    Bryce B. Reeve
    Elissa Thorner
    Albert W. Wu
    Claire Snyder
    Quality of Life Research, 2021, 30 : 21 - 40
  • [3] International guidance on the selection of patient-reported outcome measures in clinical trials: a review
    Crossnohere, Norah L.
    Brundage, Michael
    Calvert, Melanie J.
    King, Madeleine
    Reeve, Bryce B.
    Thorner, Elissa
    Wu, Albert W.
    Snyder, Claire
    QUALITY OF LIFE RESEARCH, 2021, 30 (01) : 21 - 40
  • [4] Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance
    Holloway, Laura
    Humphrey, Louise
    Heron, Louise
    Pilling, Claire
    Kitchen, Helen
    Hojbjerre, Lise
    Strandberg-Larsen, Martin
    Hansen, Brian Bekker
    HEALTH AND QUALITY OF LIFE OUTCOMES, 2014, 12
  • [5] How to Include Patient-Reported Outcome Measures in Clinical Trials
    McGee, Richard G.
    CURRENT OSTEOPOROSIS REPORTS, 2020, 18 (05) : 480 - 485
  • [6] Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review
    Strand, Vibeke
    Simon, Lee S.
    Meara, Alexa Simon
    Touma, Zahi
    LUPUS SCIENCE & MEDICINE, 2020, 7 (01):
  • [7] Patient-reported outcome measures for use in gynaecological oncology: a systematic review
    Preston, N. J.
    Wilson, N.
    Wood, N. J.
    Brine, J.
    Ferreira, J.
    Brearley, S. G.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2015, 122 (05) : 615 - 622
  • [8] Patient-Reported Outcome Measures in Endometriosis
    Nicolas-Boluda, Alba
    Oppenheimer, Anne
    Bouaziz, Jerome
    Fauconnier, Arnaud
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [9] A systematic review of randomised controlled trials evaluating the use of patient-reported outcome measures (PROMs)
    S. Ishaque
    J. Karnon
    G. Chen
    R. Nair
    A. B. Salter
    Quality of Life Research, 2019, 28 : 567 - 592
  • [10] A systematic review of randomised controlled trials evaluating the use of patient-reported outcome measures (PROMs)
    Ishaque, S.
    Karnon, J.
    Chen, G.
    Nair, R.
    Salter, A. B.
    QUALITY OF LIFE RESEARCH, 2019, 28 (03) : 567 - 592